Chris joins NeoGenomics from Ortho Clinical Diagnostics (now QuidelOrtho), where he served as Chairman and CEO from 2019 to 2022. During his leadership, Ortho Clinical raised $1.45 billion in funding in a Q1 2021 initial public offering and achieved accelerated revenue growth from 1% annually to low double-digit levels, while simultaneously improving profitability. Chris also successfully guided the company through a combination with Quidel that closed in May 2022.
Prior to his time with Ortho Clinical, Chris served in key executive leadership positions at Cochlear Limited, a global market leader in implantable hearing solutions with over $1.2 billion in annual revenue. Having initially joined Cochlear as President of Cochlear Americas in 2004, Chris helped grow division revenue from $80 million to over $400 million before being named CEO in 2015. During his tenure as CEO from 2015 to 2018, Chris oversaw a 35% organic improvement in annual revenues and improved profitability.